Troglitazone, a PPAR agonist, inhibits human prostate cancer cell growth through inactivation of NFκB via suppression of GSK-3β expression

Cancer Biology and Therapy

Volumn 12, Issue 4, 2011, Pages 288-296

  Ban, Jung Ok ^a   Oh, Ju Hoon ^a   Son, Seung Mo ^a   Won, Dohee ^a   Song, Ho Seub ^b   Han, Sang Bae ^a   Moon, Dong Cheul ^a   Kang, Keon Wook ^c   Song, Min Jong ^d   Hong, Jin Tae ^a  

^a Chungbuk National University   (South Korea)

^b Gachon University College of Medicine   (South Korea)

^c Chosun University   (South Korea)

^d The Catholic University of Korea   (South Korea)

Author keywords

GSK 3 ; Human prostate cancer; NF B; PPAR ; Troglitazone

Indexed keywords

AR A 014418; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 4; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; HISTONE H1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RELA; TROGLITAZONE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELLULAR DISTRIBUTION; ENZYME INACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CHROMANS; DOSE-RESPONSE RELATIONSHIP, DRUG; G0 PHASE; G1 PHASE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; IMMUNOBLOTTING; MALE; MICROSCOPY, FLUORESCENCE; NF-KAPPA B; PPAR GAMMA; PROSTATIC NEOPLASMS; RNA INTERFERENCE; THIAZOLES; THIAZOLIDINEDIONES; UREA;

EID: 84860401241     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.4.15961     Document Type: Article

References (41)

1. American Cancer Society. Cancer facts and figures 2008.
2. Berger J., Moller D.E. The mechanisms of action of PPARs. Annu Rev Med 2002; 53:409-435 (Pubitemid 34177889)
3. Ban J.O., Kwak D.H., Oh J.H., Park E.J., Cho M.C., Song H.S., et al. Suppression of NFkappaB and GSK-3beta is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone. Chem Biol Interact 2010; 188:75-85.
4. Krieger-Hinck N., Schumacher U., Müller A., Valentiner U. The effect of the PPAR-gamma agonist rosiglitazone on neuroblastoma SK-N-SH cells in a metastatic xenograft mouse model. Oncol Res 2010; 18:387-393
5. Kiss E., Popovic Z.V., Bedke J., Bonrouhi M., Babelova A., Schmidt C., et al. Peroxisome proliferator-activated receptor (PPAR)gamma can inhibit chronic renal allograft damage. Am J Pathol 2010; 176:2150-2162
6. Xu Y., Iyengar S., Roberts R.L., Shappell S.B., Peehl D.M. Primary culture model of peroxisome proliferator-activated receptor gamma activity in prostate cancer cells. J Cell Physiol 2003; 196:131-143 (Pubitemid 36676451)
7. Mueller E., Smith M., Sarraf P., Kroll T., Aiyer A., Kaufman D.S., et al. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA 2000; 97:10990-10995
8. Butler R., Mitchell S.H., Tindall D.J., Young C.Y. Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor gamma ligand, 15-deoxy-delta12,14-prostaglandin J2. Cell Growth Differ 2000; 11:49-61. (Pubitemid 30078666)
9. Panigrahy D., Singer S., Shen L.Q., Butterfield C.E., Freedman D.A., Chen E.J., et al. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 2002; 110:923-932
10. Kubota T., Koshizuka K., Williamson E.A., Asou H., Said J.W., Holden S., et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998; 58:3344-3352 (Pubitemid 28371075)
11. Hisatake J.I., Ikezoe T., Carey M., Holden S., Tomoyasu S., Koeffler H.P. Downregulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. Cancer Res 2000; 60:5494-5498
12. Smith M.R., Manola J., Kaufman D.S., George D., Oh W.K., Mueller E., et al. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer 2004; 101:1569-1574 (Pubitemid 39318903)
13. Yang Y.C., Tsao Y.P., Ho T.C., Choung I.P. Peroxisome proliferator-activated receptor-gamma agonists cause growth arrest and apoptosis in human ovarian carcinoma cell lines. Int J Gynecol Cancer 2007; 17:418-425
14. Smith A.G., Beaumont K.A., Smit D.J., Thurber A.E., Cook A.L., Boyle G.M., et al. PPARgamma agonists attenuate proliferation and modulate Wnt/beta-catenin signalling in melanoma cells. Int J Biochem Cell Biol 2009; 41:844-852
15. Shiau C.W., Yang C.C., Kulp S.K., Chen K.F., Chen C.S., Huang J.W., et al. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. Cancer Res 2005; 65:1561-1569 (Pubitemid 40270186)
16. Takahashi-Yanaga F., Sasaguri T. GSK-3β regulates cyclin D1 expression: A new target for chemotherapy. Cell Signal 2008; 20:581-589 (Pubitemid 351241128)
17. Sharma M., Chuang W.W., Sun Z. Phosphatidylinositol-3-kinase/Akt stimulates androgen pathway through GSK3β inhibition and nuclear β-catenin accumulation. J Biol Chem 2002; 277:30935-30941 (Pubitemid 34970795)
18. Beurel E., Jope R.S. Differential regulation of STAT family members by glycogen synthase kinase-3. J Biol Chem 2008; 283:21934-21944
19. Garg A., Aggarwal B.B. Nuclear transcription factorkappaB as a target for cancer drug development. Leukemia 2002; 16:1053-1068 (Pubitemid 34618844)
20. Dong Q.G., Sclabas G.M., Fujioka S., Schmidt C., Peng B., Wu T., et al. The function of multiple IkappaB: NFkappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene 2002; 21:6510-6519 (Pubitemid 35155455)
21. Baldwin A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NFkappaB. J Clin Invest 2001; 107:241-246 (Pubitemid 32157954)
22. Suh J., Rabson A.B. NFkappaB activation in human prostate cancer: Important mediator or epiphenomenon? J Cell Biochem 2004; 91:100-117
23. Ougolkov A.V., Bone N.D., Fernandez-Zapico M.E., Kay N.E., Billadeau D.D. Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood 2007; 110:735-742 (Pubitemid 47105412)
24. Min H.J., Koh S.S., Cho I.R., Srisuttee R., Park E.H., Jhun B.H., et al. Inhibition of GSK-3beta enhances reovirus-induced apoptosis in colon cancer cells. Int J Oncol 2009; 35:617-624
25. Bilim V., Ougolkov A., Yuuki K., Srisuttee R., Park E.H., Jhun B.H., et al. Glycogen synthase kinase-3: A new therapeutic target in renal cell carcinoma. Br J Cancer 2009; 101:2005-2014
26. Bogner-Strauss J.G., Prokesch A., Sanchez-Cabo F., Rieder D., Hackl H., Duszka K., et al. Reconstruction of gene association network reveals a transmembrane protein required for adipogenesis and targeted by PPARgamma. Cell Mol Life Sci 2010; 67:4049-4064
27. Fajas L., Debril M.B., Auwerx J. Peroxisome proliferator-activated receptor-gamma: From adipogenesis to carcinogenesis. J Mol Endocrinol 2001; 27:1-9. (Pubitemid 32771453)
28. Yue T.L., Bao W., Gu J.L., Cui J., Tao L., Ma X.L., et al. Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes 2005; 54:554-562
29. Wei S., Lin L.F., Yang C.C., Wang Y.C., Chang G.D., Chen H., et al. Thiazolidinediones modulate the expression of beta-catenin and other cell cycle regulatory proteins by targeting the F-box proteins of Skp1-Cul1-F-box protein E3 ubiquitin ligase independently of peroxisome proliferator-activated receptor gamma. Mol Pharmacol 2007; 72:725-733 (Pubitemid 47347307)
30. Terry S., Yang X., Chen M.W., Vacherot F., Buttyan R. Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer. J Cell Biochem 2006; 99:402-410 (Pubitemid 44435558)
31. Ougolkov A.V., Fernandez-Zapico M.E., Bilim V.N., Smyrk T.C., Chari S.T., Billadeau D.D. Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: Association with kinase activity and tumor dedifferentiation. Clin Cancer Res 2006; 12:5074-5081 (Pubitemid 44453333)
32. Song S., Mazurek N., Liu C., Sun Y., Ding Q.Q., Liu K., et al. Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer Res 2009; 69:1343-1349
33. Zhang J.Y., Tao L.Y., Liang Y.J., Yan Y.Y., Dai C.L., Xia X.K., et al. Secalonic acid D induced leukemia cell apoptosis and cell cycle arrest of G(1) with involvement of GSK-3beta/beta-catenin/c-Myc pathway. Cell Cycle 2009; 8:2444-2450
34. Gaisina I.N., Gallier F., Ougolkov A.V., Kim K.H., Kurome T., Guo S., et al. From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells. J Med Chem 2009; 52:1853-1863
35. Huang J.W., Shiau C.W., Yang Y.T., Kulp S.K., Chen K.F., Brueggemeier R.W., et al. Peroxisome Proliferator-Activated Receptor g-Independent Ablation of Cyclin D1 by Thiazolidinediones and Their Derivatives in Breast Cancer Cells. Mol Pharmacol 2005; 67:1342-1348 (Pubitemid 40410435)
36. Saleem M., Murtaza I., Tarapore R.S., Kulp S.K., Chen K.F., Brueggemeier R.W., et al. Lupeol inhibits proliferation of human prostate cancer cells by targeting beta-catenin signaling. Carcinogenesis 2009; 30:808-817
37. Lim K., Han C., Xu L., Lsse K., Demetris A.J., Wu T. Cyclooxygenase-2- derived prostaglandin E2 activates beta-catenin in human cholangiocarcinoma cells: Evidence for inhibition of these signaling pathways by N-3 polyunsaturated fatty acids. Cancer Res 2008; 68:553-560 (Pubitemid 351380084)
38. Schwabe R.F., Brenner D.A. Role of glycogen synthase kinase-3 in TNFα-induced NFκB activation and apoptosis in hepatocytes. Am J Physiol Gastrointest Liver Physiol 2002; 283:204-211
39. Ougolkov A.V., Fernandez-Zapico M.E., Savoy D.N., Urrutia R.A., Billadeau D.D. Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res 2005; 65:2076-2081 (Pubitemid 40490111)
40. Steinbrecher K.A., Wilson W., III, Cogswell P.C., Baldwin A.S. Glycogen synthase kinase 3{β} Functions to specify gene-specific, NFkappaB-Dependent transcription. Mol Cell Biol 2005; 25:8444-8455 (Pubitemid 41369166)
41. Ban J.O., Oh J.H., Hwang B.Y., Moon D.C., Jeong H.S., Lee S., et al. Inflexinol inhibits colon cancer cell growth through inhibition of nuclear factor-kappaB activity via direct interaction with p50. Mol Cancer Ther 2009; 8:1613-1624